EyePoint Pharmaceuticals has entered into a formal three-year contract with Vizient effective November 1, 2019, to offer DEXYCU®. Vizient provides expertise, analytics and advisory services, as well as a contract portfolio that represents more than $100 billion in annual purchasing volume, to improve patient outcomes and lower costs.
“Since the launch of DEXYCU in the first quarter of this year, EyePoint’s dedicated sales team has been making consistent headway in penetrating targeted ambulatory surgical centers to deliver DEXYCU to patients who can benefit from the product’s differentiated profile and efficacy,” said Nancy Lurker, President and CEO of EyePoint Pharmaceuticals. “As a result, physician interest for DEXYCU, thus far, has been strong, and we are pleased to enter into an agreement with Vizient and begin offering contract savings to Vizient members. We look forward to the continued expansion of our commercial reach of DEXYCU to meet the ophthalmology community’s demand for our product with the addition of Vizient members, which account for more than 50% of the acute care providers in the United States.”